# A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine

> **NCT04686136** · PHASE3 · COMPLETED · sponsor: **AbbVie** · enrollment: 596 (actual)

## Conditions studied

- Episodic Migraine
- Chronic Migraine

## Interventions

- **DRUG:** Atogepant 60 mg

## Key facts

- **NCT ID:** NCT04686136
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2021-02-19
- **Primary completion:** 2025-10-20
- **Final completion:** 2025-10-20
- **Target enrollment:** 596 (ACTUAL)
- **Last updated:** 2025-12-18


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04686136

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04686136, "A Long-Term Safety and Tolerability Extension Study Evaluating Atogepant for the Prevention of Chronic or Episodic Migraine". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT04686136. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*